2015年7月15日 · 4-1BB是诱导型共刺激受体，其配体为4-1BBL，主要表达抗原提呈细胞（APC）上，受体配体结合后可提供共刺激信号，促进T细胞等免疫细胞增殖和细胞因子产生，是免疫细胞激活的“油门”。 4-1BB（CD137）的免疫调节机制. （Clin Cancer Res; 21 (14) July 15, 2015） CD40靶点介绍. CD40（TNFRSF5, Tumor necrosis factor receptor super family, member 5）及其配体CD40L（CD145），也属于 肿瘤坏死因子受体超家族，CD40主要表达在APC …

DuoBody-CD40×4-1BB (GEN1042/BNT312) is a novel investigational Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB to enhance priming and reactivation of tumor-specific immunity in patients with cancer.

Preliminary findings from a first-in-human phase I/II trial of GEN1042, a bispecific antibody that simultaneously targets CD40 and 4-1BB on immune cells, suggest that this drug is well tolerated and active in patients with advanced solid tumors.

DuoBody-CD40×4-1BB (GEN1042/BNT312) is a novel investigational Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB to enhance priming and reactivation of tumor-specific immunity in patients with cancer.

4-1BB (也称为 CD137) 是一种可诱导的共刺激受体，是细胞表面糖蛋白，属于肿瘤坏死因子受体 (TNFR)家族的跨膜分子，由肿瘤坏死因子受体超家族成员9（TNFRSF9）基因编码。 4-1BB 主要表达在活化的CD4+和CD8+T细胞及自然杀伤细胞（NK细胞），在调节性T细胞上组成型表达。 此外，4-1BB也表达在活化的巨噬细胞、B细胞和树突状细胞上。 4-1BB Ligand是4-1BB的配体，它主要表达于活化的抗原呈递细胞（APC），如树突状细胞（DC细胞）、B细胞、单核细胞、吞 …

In this study, we aimed on to exploit the high agonism of AT-bound αCD40- and α41BB-AD fusion proteins to generate CD40 and 41BB agonists that not only intimately link checkpoint inhibition with CD40/41BB engagement but also act preferentially in …

本文以近期发表了人体临床前特征和首次人体研究结果的 GEN1046（PD-L1×4-1BB） 为例，浅析4-1BB为基础靶点的双抗的优势。 GEN1046是一个全长IgG1亚型、 PD-L1×4-1BB双抗，使用DuoBody®技术平台，通过单克隆全人源PD-L1和人源化4-1BB抗体的Fab臂交换产生，基于双特异性模式的体外生物活性选择母代PD-L1和4-1BB抗体。 母代抗体包含CH3结构域的对应突变F405L/K409R（促使Fab臂的异源二聚化，生成双特异性分子）和Fc沉默突变 …

2024年1月4日 · In this review, we briefly examine the role of 4-1BB in T-cell biology, explore its clinical applications, and discuss future prospects in the field of 4-1BB agonist immunotherapy.

2023年10月21日 · We developed XFab-α4-1BB/CD40L, a bispecific antibody targeting 4-1BB and CD40 for dendritic cell activation and priming of tumour-reactive T cells to inhibit tumours. XFab-α4-1BB/CD40L was developed by engineering an anti-4-1BB Fab arm into a CD40L trimer based on XFab® platform.

2022年1月1日 · Upon anchoring to membrane PDL1, the bispecific antibody fusion proteins activated CD40/41BB signaling as efficient as the parental anti-CD40/anti-41BB antibodies when bound to FcγRs or cells expressing membrane-bound CD40L/41BBL.